EUVIMEDEUVIMED entdecken
Crossref

X-ray Induced Persistent Type I Photodynamic Therapy with Enhanced Hypoxia Tolerance and Chemoradiotherapy

Wei Cheng, Shuai He, Qiushui Chen iD, Xiaorong Song iD, Chunhua Lu iD, Huanghao Yang iD

Nano Letters · 2025

DOI: 10.1021/acs.nanolett.5c00433 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nano Letters, 2025. Verfasst von Wei Cheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: New Cornerstone Science Laboratory, MOE Key Laboratory for Analytical Science of Food Safety and Biology, College of Chemistry, Fuzhou University, Fu…. Hauptthemen laut MEDLINE: Photochemotherapy, Photosensitizing Agents, Chemoradiotherapy, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The hypoxic tumor microenvironment (TME), inadequate penetration depth of Vis/NIR light, and lack of sustaining reactive oxygen species (ROS) production capability of photosensitizers pose significant obstacles to the widespread clinic applications of photodynamic therapy (PDT). Herein, we developed a "persistent type I X-PDT" platform to simultaneously overcome these three limitations. Such a nanoplatform could generate efficient ROS (•OH and O2•-) under X-ray irradiation in both normoxic and hypoxic environments. The ROS production persists in tumor cells for more than 4 h, even after the X-ray source is removed. Notably, the persistent type I X-PDT does not increase the levels of hypoxia-inducible factor-1 alpha (HIF-1α) and vascular endothelial growth factor (VEGF) in tumor cells both in vitro and in vivo. Moreover, to further enhance the radiotherapy efficacy in hypoxic conditions, a Pt (IV) prodrug was also introduced, which can be reduced to cisplatin selectively in tumor cells, functioning not only as a chemodrug but also as a radiosensitizer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhotochemotherapyPhotosensitizing AgentsChemoradiotherapyNeoplasmsHumansAnimalsMiceTumor MicroenvironmentX-RaysReactive Oxygen SpeciesCell Line, TumorHypoxia-Inducible Factor 1, alpha SubunitVascular Endothelial Growth Factor AProdrugsCisplatinCell HypoxiaTumor Hypoxia

Stichwörter der Autor:innen

chemotherapyhypoxiapersistent X-PDTradiation therapytype I ROS

Substanzen

Reactive Oxygen SpeciesPhotosensitizing AgentsHypoxia-Inducible Factor 1, alpha SubunitVascular Endothelial Growth Factor AProdrugsCisplatin

Autor:innen und Institutionen

  • New Cornerstone Science Laboratory, MOE Key Laboratory for Analytical Science of Food Safety and Biology, College of Chemistry, Fuzhou University, Fuzhou 350108, China.
  • Department of Chemical and Biomolecular Engineering, National University of Singapore, 117585, Singapore.

ORCID-Profile: Qiushui Chen, Xiaorong Song, Chunhua Lu, Huanghao Yang

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Cheng, W., He, S., Chen, Q., Song, X., Lu, C., & Yang, H. (2025). X-ray Induced Persistent Type I Photodynamic Therapy with Enhanced Hypoxia Tolerance and Chemoradiotherapy. Nano Letters. https://doi.org/10.1021/acs.nanolett.5c00433

Vancouver

Cheng W, He S, Chen Q, Song X, Lu C, Yang H. X-ray Induced Persistent Type I Photodynamic Therapy with Enhanced Hypoxia Tolerance and Chemoradiotherapy. Nano Letters. 2025. doi:10.1021/acs.nanolett.5c00433

BibTeX
@article{Cheng2025,
  author = {Cheng, Wei and He, Shuai and Chen, Qiushui and Song, Xiaorong and Lu, Chunhua and Yang, Huanghao},
  title = {X-ray Induced Persistent Type I Photodynamic Therapy with Enhanced Hypoxia Tolerance and Chemoradiotherapy},
  journal = {Nano Letters},
  year = {2025},
  doi = {10.1021/acs.nanolett.5c00433}
}
Kostenlos starten →